search

Active clinical trials for "Leukemia, Lymphoid"

Results 1101-1110 of 2205

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic...

Recurrent B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia4 more

This phase I trial studies the side effects and best dose of lenalidomide when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide together with ibrutinib may work better in treating chronic lymphocytic leukemia or small lymphocytic lymphoma.

Completed47 enrollment criteria

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With...

Chronic Lymphocytic Leukemia

This is a multicenter, open-label, single-arm, expanded access treatment study designed to provide obinutuzumab to patients with previously untreated Chronic Lymphocytic Leukemia (CLL) in combination with chlorambucil and to evaluate the safety and efficacy of obinutuzumab administered in combination with chlorambucil. This study will enroll patients with previously untreated CD20-positive CLL requiring treatment according to the IWCLL guidelines (Hallek et al 2008), as assessed by the investigator.

Completed16 enrollment criteria

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

MDS (Myelodysplastic Syndrome)Myeloproliferative Disorder4 more

Background: - Researchers are working to make stem cell transplant procedures safer and more effective. One complication of transplants is graft-versus-host disease (GVHD). This complication happens when certain white blood cells from the donor attack the recipient's own body. Researchers want to test a blood separator machine that may help remove more of the donor's white blood cells before transplant. They will study donors and recipients during stem cell transplant to see how well this process can prevent GVHD and other complications. Objectives: - To see if a new blood separator machine can improve outcomes of stem cell transplants. Eligibility: Individuals between 10 and 75 years of age who are having a stem cell transplant for leukemia or other blood-related cancers. Donors for the stem cell transplant. Design: Recipients and donors will be screened with a physical exam and medical history. Donors will have two blood collection procedures. The first will collect only white blood cells, and return the rest of the blood. After the first collection, participants will have filgrastim injections to help their stem cells enter their blood. Then, they will have a second blood collection for the stem cells. Recipients will have radiation and chemotherapy to prepare for the stem cell transplant. They will then have the stem cell transplant with the donor cells that have been treated with the blood separator machine. Recipients will be monitored closely after the procedure. They may receive some of their donor's white blood cells if needed to fight serious infections. Recipients will have the regular standard of care after their transplant. Blood samples will be taken and any side effects will be monitored and treated.

Completed43 enrollment criteria

Pneumococcal Vaccine in Untreated CLL Patients

Chronic Lymphocytic Leukemia

The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia (CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine, Prevenar13, compared with a conventional 23-valent capsular polysaccharide vaccine in terms of immune response.

Completed6 enrollment criteria

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Advanced CancersLeukemia

The goal of this clinical research study is to find the highest tolerable dose of T cells that can be given in combination with standard chemotherapy to patients with CLL. The safety of this combination will also be studied. The T cells being used in this study are a type of white blood cell that will be taken from your blood and then genetically changed in a laboratory. The process of changing the DNA (the genetic material of cells) of the T cells is called a gene transfer. After the gene transfer is complete, the genetically changed T-cells will be put back into your body. These T cells may help prevent cancer cells from coming back.

Completed15 enrollment criteria

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic...

Chronic Lymphocytic Leukemia

The purpose of this study is to find out what effects a new drug AT7519M has on chronic lymphocytic leukemia.

Completed48 enrollment criteria

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic...

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

This is a multi-center, open-label, dose escalation study.

Completed37 enrollment criteria

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or...

B-cell Chronic Lymphocytic LeukemiaHematopoietic/Lymphoid Cancer3 more

RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL), or prolymphocytic leukemia (PLL).

Completed23 enrollment criteria

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy...

Lymphoid Malignancies (New or Relapsed)Acute Lymphoblastic Leukemia4 more

This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicine and Dexamethasone), with an ultimate goal to perform a phase II study to evaluate response rates and survival in adults with Acute Lymphoblastic Leukemia (ALL) and aggressive lymphoid malignancies.

Completed43 enrollment criteria

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing...

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia18 more

This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant (PBSCT) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation (TBI) together with fludarabine phosphate (FLU), cyclosporine (CSP), mycophenolate mofetil (MMF), or sirolimus before transplant may stop this from happening.

Completed48 enrollment criteria
1...110111112...221

Need Help? Contact our team!


We'll reach out to this number within 24 hrs